We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Werewolf Therapeutics Inc (HOWL) USD0.0001

Sell:$2.73 Buy:$2.74 Change: $0.03 (1.10%)
Market closed |  Prices as at close on 22 July 2024 | Switch to live prices |
Change: $0.03 (1.10%)
Market closed |  Prices as at close on 22 July 2024 | Switch to live prices |
Change: $0.03 (1.10%)
Market closed |  Prices as at close on 22 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in development as a single agent in metastatic solid tumors and non-Hodgkin lymphoma. Its pipeline also includes JZP898 and WTX-712.

Contact details

200 Talcott Avenue, 2Nd Floor
United States
+1 (617) 9520555

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$120.37 million
Shares in issue:
43.46 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Daniel Hicklin
    President, Chief Executive Officer, Director
  • Timothy Trost
    Chief Financial Officer, Treasurer
  • Chulani Karunatilake
    Chief Technology Officer
  • Randi Isaacs
    Chief Medical Officer
  • Ellen Lubman
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.